Form 4: Travere Therapeutics CEO Exercises, Sells Stock

Travere Therapeutics CEO Eric M. Dube exercised 60,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 plan.

Summary

• Eric M. Dube, Chief Executive Officer and Director of Travere Therapeutics, Inc. (TVTX), reported transactions involving the company's common stock and employee stock options.
• On January 23, 2026, Dube exercised 8,135 employee stock options at an exercise price of $15.46 per share, simultaneously acquiring 8,135 shares of common stock.
• Immediately following the exercise on January 23, 2026, Dube sold all 8,135 acquired common shares at a weighted average price of $30.0127 per share, with prices ranging from $30.00 to $30.13.
• On January 27, 2026, Dube exercised an additional 51,865 employee stock options at an exercise price of $15.46 per share, acquiring 51,865 shares of common stock.
• Immediately following the exercise on January 27, 2026, Dube sold all 51,865 acquired common shares at a weighted average price of $30.097 per share, with prices ranging from $30.00 to $30.49.
• All sales were conducted pursuant to a Rule 10b5-1(c) written plan adopted on June 16, 2025.
• Following these transactions, Dube's direct beneficial ownership of common stock remained at 419,173 shares, and his direct beneficial ownership of employee stock options decreased to 120,000 options.

Sentiment

Score: 7

Explanation: The filing reports routine insider transactions under a pre-arranged 10b5-1 plan, indicating planned monetization of vested equity rather than a reaction to new information. The significant difference between exercise and sale prices reflects the executive's compensation structure and stock appreciation.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, which provides an affirmative defense against insider trading allegations, demonstrating sound corporate governance practices for executive equity management.
• The executive realized a significant profit from the difference between the option exercise price ($15.46) and the sale prices ($30.0127 and $30.097), indicating appreciation in the company's stock value.

Future Outlook

na

Industry Context

na

Stakeholder Impact

• Shareholders may note the CEO's monetization of vested equity, which is a common practice for executives managing their compensation and personal finances.

Key Dates

Recommendation

The Form 4 details pre-scheduled insider transactions (exercise and sale of options) by the CEO. These transactions were conducted under a Rule 10b5-1 plan, indicating they were pre-arranged and not based on new, non-public information. While insider selling can sometimes be viewed negatively, the planned nature and the fact that it represents monetization of vested compensation make it a neutral event for investment decisions. The filing itself does not provide new fundamental information about the company's performance or outlook to warrant a change in investment stance.

Keywords

Travere Therapeutics, TVTX, Eric Dube, Form 4, insider trading, stock options, beneficial ownership, CEO, stock sale, 10b5-1 plan